Clinical complications occur in 30% of hospitalized patients and are preceded by abnormal vital signs but often not detected in the hospital ward, resulting in harm to patients and increased healthcare expenses. Simple continuous vital sign monitoring solutions are limited by too many false alerts, where alert algorithms are based upon sparse evidence or thresholds that are not data-driven, nor personalized. Available sensors are not suited for the general ward with active patients recovering from disease resulting in low compliance and loss of data-capture. These factors lead to alert fatigue, overtreatment and missed opportunity for early complication detection. The ONWARD project develops a wireless patient monitoring system combining advanced biomedical signal processing and artificial intelligence with a multisensory ear-device for maximum user compliance and data collection. Using a multisensory ear-device the ONWARD project will collect a range of standard and novel vital signs minute-by-minute. Combined with annotated information on complications, ONWARD will develop advanced AI-alerts with high accuracy for upcoming complications. Development and validation will occur at the hospital ward and include technical validation, user experiences and a randomized clinical trial to document effect on complication reduction. The end result will be a world-leading AI-supported continuous vital signs monitoring system with direct patient benefit and large societal impact.

Denmark has the potential to become one large phase 4 study, where data and insight from patients treated today will help tomorrow's patients and increase the competitiveness of the Life Science industry. The OSCAR DREAM project takes an important step in realizing this vision by developing technical solutions that increase productivity in clinical research. It does so by developing and implementing 1) a solution that ensures that data from electronic medical records will be cleaned, structured and mapped against international standards for the exchange and sharing of clinical data (FHIR and OMOP), 2) a solution for extraction of such data at micro level in fully anonymised form, 3) a model for shared services to support clinicians in their clinical research and for integrating the new clinical insight in to clinical practice faster than today. The clinical focus is on oncology. OSCAR DREAM will contribute substantially to the vision for a National Analytical Platform for Health Data currently being developed by the Danish Health Data Authority. The services developed in the DREAM project will be commercialized through the OSCAR organization, expanding the data based services and while realizing strong synergies with the OSCAR and CLIC projects. The partners are leading organizations focused on providing better access to real world evidence. They form a commercial partnership led by DataFair to ensure a complete value offering in Denmark and internationally.

Alzheimer’s disease (AD) and Parkinson’s disease (PD), represent major global public health challenges. Yet, 30-50% with AD or PD is believed to go undiagnosed. Early diagnosis is beneficial for patients and carers and can result in substantial cost savings to healthcare systems. Current diagnostic measures are unscalable, expensive and time-consuming and thus have limited accessibility as frontline diagnostic tools. In collaboration with EDoN (a UK led global initiative on Early Detection of Neurodegenerative diseases, see www.edon-initiative.org). PANDA will address these needs and develop and assess a wearable solution that can measure and analyse subtle changes in sleep and autonomic function, instrumental for precision medicine and early biomarkers of neurodegeneration, thus moving from current reactive diagnostic options to early detection, protection and prevention. PANDA further addresses the need for cost-effectiveness, timeliness, and capacity in healthcare systems, offering unattended home monitoring as an alternative to the classic interaction between patient and health care system. Thus, PANDA addresses operational limitations, while moving the state-of-the-art for frontline and early diagnostics. Our commercial goal is to provide a solution for new intervention targets for future clinical studies and enable precision medicine at scale towards an unobtrusive and cost-efficient diagnostics of neurodegenerative diseases.

Agriculture accounts for about 20% of total CO2 emissions. Cereals such as barley (Hordeum vulgare) and wheat (Triticum aestivum) are widely cultivated crops for feed and food production. All cultivated cereals are annuals and live for only one season. They require substantial amounts of energy, fertilizer, and labor and store carbon underground only to a very limited extent: less than 10% of the total carbon is fixed underground during a life cycle. By contrast, perennial grasses live for several years and have a deep and long-lasting root system that binds large amounts of carbon. However, these plants have not yet been domesticated and their yields are much lower than those of annuals. Perennial grasses are superior at using mineral nutrients efficiently, improving soil health, and tolerating abiotic stresses, such as drought. A transition to cropping systems based on perennial cereals, rather than annuals, would increase carbon storage and be a major step towards both a more climate-friendly and climate-resilient agriculture. In this project, we will strive to domesticate a wild perennial relative of barley, Hordeum bulbosum, as a novel climate-smart carbon source for food and feed industries. Based on H. bulbosum populations already selected for growth in Scandinavia under farmer field conditions, the project will aim to increase their productivity and in this way generate a new climate-friendly market-competitive perennial barley.